Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs has entered into a Canadian marketing and supply agreement with Watson Pharma, a subsidiary of Watson Pharmaceuticals, to market the anticancer therapies Trelstar 3.75mg and Trelstar LA 11.25mg.
Subscribe to our email newsletter
Trelstar (triptorelin pamoate for injectable suspension) 3.75mg, one-month slow release, is an injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer and for the treatment of endometriosis. Trelstar LA 11.25mg is a three-month slow release treatment for advanced prostate cancer.
This deal represents Paladin’s third product deal with Watson. Trelstar will further strengthen Paladin’s urology presence in Canada by complementing the existing promotional activities with the incontinence treatment, Oxytrol. In addition, Trelstar 3.75mg will also complement the women’s health franchise since it has been approved for the treatment of endometriosis.
Paladin said that it expects to launch Trelstar and Trelstar LA in the fourth quarter of this year.